분자생물학적 표지자를 이용한 갑상선암 환자의 맞춤형 추적관찰
Personalized Follow Up in Thyroid Cancer Using Molecular Markers
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Clinical guidelines for initial management and long-term follow-up of thyroid cancer have been published from many societies world-widely, but there are still many unanswered clinical situation by conventional approach. The prognostic role of BRAF V600E mutation status in patients with papillary thyroid microcarcinoma has been reported and surgical extent could be guided by preoperative assessment of BRAF V600E status from fine needle aspirates. The most important prognostic parameters thyroid cancer after total thyroidectomy and radioactive iodine treatment is measurement of serum thyroglobulin (Tg). Thyrolgobulin autoantiboies (TgAb)is detected up to 25 percent of thyroid cancer patients and may be potential cause of false negative Tg. To overcome this caveat, measurement of transcript of thyroid tissue specific gene could be a substitute for Tg. Serum Tg measurement is also not helpful for thyroid cancer patients who received partial thyroidectomy. Because Tg is tissue specific marker, not cancer specific marker, i.e. normal remnant thyroid tissue could be potential source of Tg. Recent approach to measure BRAF V600E mutation from peripheral blood could be a good candidate tumor marker in patients with normal remnant thyroid tissue. Recent introduction of novel molecular markers for thyroid cancer could be a promising answer to previous guideline for individualize follow-up of thyroid cancer patients.
Abstract
Clinical guidelines for initial management and long-term follow-up of thyroid cancer have been published from many societies world-widely, but there are still many unanswered clinical situation by conventional approach. The prognostic role of BRAF V600E mutation status in patients with papillary thyroid microcarcinoma has been reported and surgical extent could be guided by preoperative assessment of BRAF V600E status from fine needle aspirates. The most important prognostic parameters thyroid cancer after total thyroidectomy and radioactive iodine treatment is measurement of serum thyroglobulin (Tg). Thyrolgobulin autoantiboies (TgAb)is detected up to 25 percent of thyroid cancer patients and may be potential cause of false negative Tg. To overcome this caveat, measurement of transcript of thyroid tissue specific gene could be a substitute for Tg. Serum Tg measurement is also not helpful for thyroid cancer patients who received partial thyroidectomy. Because Tg is tissue specific marker, not cancer specific marker, i.e. normal remnant thyroid tissue could be potential source of Tg. Recent approach to measure BRAF V600E mutation from peripheral blood could be a good candidate tumor marker in patients with normal remnant thyroid tissue. Recent introduction of novel molecular markers for thyroid cancer could be a promising answer to previous guideline for individualize follow-up of thyroid cancer patients.
참고문헌 (19)
- Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
- Ito Y, "Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma", World J Surg, 29(7), pp.917~920 (2005)
- Basolo F, "Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases", J Clin Endocrinol Metab, 95(9), pp.4197~4205 (2010)
- Lee X, "Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma", Ann Surg Oncol, 16(2), pp.240~245 (2009)
- Lupi C, "Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma", J Clin Endocrinol Metab, 92(11), pp.4085~4090 (2007)
- Rodolico V, "BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid < or =1 cm and their paired lymph node metastases", Cancer, 110(6), pp.1218~1226 (2007)
- Kim SW, "BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population", J Clin Endocrinol Metab, 95(8), pp.3693~3700 (2010)
- 김정민, "Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 93(12), pp.4683~4689 (2008), ENDOCRINE SOC
- Gupta M, "Circulating thyroid cancer markers", Curr Opin Endocrinol Diabetes Obes, 14(5), pp.383~388 (2007)
- Barzon L, "Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse", Int J Cancer, 110(6), pp.914~920 (2004)
- Ishikawa T, "Quantitation of thyroid peroxidase mRNA in peripheral blood for early detection of thyroid papillary carcinoma", Thyroid, 16(5), pp.435~442 (2006)
- Chinnappa P, "Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer", J Clin Endocrinol Metab, 89(8), pp.3705~3709 (2004)
- 이승훈, "1개 병원 갑상선 암환자 특성의 추이 분석", 대한내분비학회지, 23(1), pp.35~43 (2008), 대한내분비학회
- Kim TY, "Prognostic parameters for recurrence of papillary thyroid microcarcinoma", BMC Cancer, 8, pp.296~ (2008)
- Cradic KW, "Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status", J Clin Endocrinol Metab, 94(12), pp.5001~5009 (2009)
- Jo YS, "Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer", J Clin Endocrinol Metab, 91(9), pp.3667~3670 (2006)
- Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area", Clin Endocrinol, 65(5), pp.660~666 (2006)
- Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma", Clin Endocrinol, 65(3), pp.364~368 (2006)
- Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol, 63(5), pp.588~593 (2005)